Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-371 with or without hypertonic saline and optional ivacaftor in primary ciliary dyskinesia
NL-OMON46905Phase 2Active, not recruiting
- Sponsor
- Parion Sciences
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of idrevloride and ivacaftor in primary ciliary dyskinesia (PCD) (4 arms), sponsored by Parion Sciences. Primary endpoints: Safety and tolerability and Absolute change in percent predicted FEV1. Started Apr 2017; status: active, not recruiting.
02
Drugs
idrevlorideivacaftor
03
Conditions
primary ciliary dyskinesia (PCD)
Beyond the preview
Go deeper on NL-OMON46905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46905.